Prot#SGN35-012: A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory CD30-Positive non-Hodgkin Lymphoma (NHL)

Project: Research project

Project Details

StatusFinished
Effective start/end date12/15/1112/15/17

Funding

  • Seattle Genetics, Inc. (Prot#SGN35-012)